Lenalidomide

Generic Name: Lenalidomide

Indication: ⑴主要用于具有5q缺失细胞遗传学异常的骨髓增生异常综合征所致的输血依赖性贫血患者的治疗。⑵与地塞米松合用治疗已经接受过至少一种疗法的多发性骨髓瘤（套细胞淋巴瘤（MCL））患者。

Clinical Trials

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Phase 1

Recruiting

Conditions: Lymphoma
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Burkitt Lymphoma

Interventions: Biological: obinutuzumab
Drug: prednisone
Drug: Revlimid
Biological: Polatuzumab
Drug: ibrutinib
Drug: venetoclax

First Posted Date: 2021-02-05

Last Posted Date: 2025-03-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 55

Registration Number: NCT04739813

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea

Completed

Conditions: Myelodysplastic Syndromes
Lymphoma, Mantle-Cell
Lymphoma, Follicular

Interventions: Drug: REVLIMID®

First Posted Date: 2019-07-29

Last Posted Date: 2025-03-11

Lead Sponsor: Celgene

Target Recruit Count: 28

Registration Number: NCT04036448

Locations: 🇰🇷
Local Institution - S10, Jeonju-si, Korea, Republic of
🇰🇷
Kyungpook National University Hospital, Daegu, Korea, Republic of
🇰🇷
Local Institution - S06, Seoul, Korea, Republic of

and more 23 locations

R2 in the Treatment of Follicular Lymphoma

Phase 2

Conditions: Follicular Lymphoma

Interventions: Drug: Revlimid

First Posted Date: 2018-10-23

Last Posted Date: 2019-07-08

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 115

Registration Number: NCT03715309

Locations: 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

Phase 1

Recruiting

Conditions: Diffuse Large B-Cell Lymphoma
Burkitt Lymphoma
Lymphoma
Non-Hodgkin Lymphoma

Interventions: Drug: Venetoclax
Drug: Ibrutinib
Drug: Prednisone
Biological: Obinutuzumab
Drug: Revlimid (lenalidomide)

First Posted Date: 2017-07-21

Last Posted Date: 2025-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 145

Registration Number: NCT03223610

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Crossover Study to Compare Pharmacokinetic Property of SYP-1512 Tab and Revlimid Cap in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy, Male

Interventions: Drug: SYP-1512
Drug: Revlimid cap

First Posted Date: 2017-07-05

Last Posted Date: 2017-07-06

Lead Sponsor: Samyang Biopharmaceuticals Corporation

Target Recruit Count: 42

Registration Number: NCT03208218

A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Revlimid (lenalidomide)

First Posted Date: 2017-04-10

Last Posted Date: 2022-06-02

Lead Sponsor: Celgene

Target Recruit Count: 911

Registration Number: NCT03106324

Locations: 🇧🇪
AZ Nikolaas, Sint Niklass, Belgium
🇧🇪
CHU du Mont-Godinne, Yvoir, Belgium
🇳🇱
Nij Smellinghe, Drachten, Netherlands

and more 121 locations

Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)

Completed

Conditions: Lymphoma

Interventions: Drug: Revlimid

First Posted Date: 2017-04-04

Last Posted Date: 2025-03-30

Lead Sponsor: Celgene

Target Recruit Count: 1149

Registration Number: NCT03098589

Locations: 🇯🇵
ASO KK Iizuka Hospital, Iizuka, Fukuoka, Japan

A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)

Phase 2

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Revlimid
Drug: Velcade
Drug: dexamethasone
Drug: Farydak

First Posted Date: 2016-03-28

Last Posted Date: 2018-07-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 6

Registration Number: NCT02720510

Locations: 🇺🇸
David Geffen School of Medicine at UCLA UCLA, Los Angeles, California, United States
🇺🇸
Northside Hospital Central Research Dept., Atlanta, Georgia, United States
🇺🇸
Oncology Hematology West Nebraska Cancer Specialists dbaNebraska Cancer Specialists, Omaha, Nebraska, United States

and more 2 locations

A Study to Collect and Evaluate the Safety and Efficacy Information of Korean Multiple Myeloma Patients Treated With REVLIMID®, After Approval of Marketing Authorization for New Drug in Korea

Completed

Conditions: Multiple Myeloma

Interventions: Drug: REVLIMID®
Drug: Dexamethasone

First Posted Date: 2015-09-22

Last Posted Date: 2017-12-04

Lead Sponsor: Celgene

Target Recruit Count: 624

Registration Number: NCT02556905

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷
Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of
🇰🇷
Soon Chun Hyang University Hospital Bucheon, Bucheon, Korea, Republic of

and more 22 locations

Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia

Phase 1

Completed

Conditions: Waldenstrom Macroglobulinemia

Interventions: Drug: Revlimid

First Posted Date: 2014-11-27

Last Posted Date: 2017-06-07

Lead Sponsor: University Hospital, Lille

Target Recruit Count: 17

Registration Number: NCT02302469

Locations: 🇫🇷
Ch Clermond Ferrand, Clermond Ferrand, France
🇫🇷
CH LENS, Lens, France
🇫🇷
Centre Hospitalier Lyon Sud, Pierre Benite, France

and more 4 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy